Rezolute Inc. files $10 million in equity offering
LOUISVILLE — Rezolute Inc., the bioscience company formerly known as AntriaBio Inc., filed a Form D for $10.1 million in capital.
The Louisville-based company has raised nearly $138,000, according to a Form D filed Jan. 10 with the Securities and Exchange Commission. To raise the funds, Rezolute is offering equity.
The funding is part of a previously-announced $10 million purchase agreement Rezolute has with Lincoln Park Capital Fund, a spokesperson for Rezolute told BizWest.
SPONSORED CONTENT
Rezolute specializes in developing drug therapies for metabolic and orphan diseases, that is, rare diseases that have few pharmaceutical treatments.
The company changed its name in December to reflect its focus on treating diseases that have unmet needs.
LOUISVILLE — Rezolute Inc., the bioscience company formerly known as AntriaBio Inc., filed a Form D for $10.1 million in capital.
The Louisville-based company has raised nearly $138,000, according to a Form D filed Jan. 10 with the Securities and Exchange Commission. To raise the funds, Rezolute is offering equity.
The funding is part of a previously-announced $10 million purchase agreement Rezolute has with Lincoln Park Capital Fund, a spokesperson for Rezolute told BizWest.
Rezolute specializes in developing drug therapies for metabolic and orphan diseases, that is, rare diseases that have few pharmaceutical treatments.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
